IPSC – century therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at Piper Sandler from $12.00 to $4.00. They now have an "overweight" rating on the stock.
Shinobi Strengthens Leadership to Propel Scalable Immune-Evasive Cell Therapies to the Clinic [Yahoo! Finance]
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at Chardan Capital from $17.00 to $11.00. They now have a "buy" rating on the stock.
Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at HC Wainwright from $9.00 to $5.00. They now have a "buy" rating on the stock.
Form 8-K Century Therapeutics, For: Dec 12
Form 4 Century Therapeutics, For: Dec 04 Filed by: Pfeiffenberger Brent
Form SC 13G Century Therapeutics, Filed by: Casdin Capital, LLC
Form SC 13G/A Century Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.
Form SC 13G/A Century Therapeutics, Filed by: Casdin Capital, LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.